Table 2.

Tetramer, IFN-γ T-cell frequency, and CRA results of PBMCs before and after IVS



% Tetramer binding

% IFN-γ

% CRA
UPN
IE1
pp65
Nonrelated
IE1
pp65
Nonrelated
IE1
pp65
Nonrelated
009          
   PBMC*  6.89   2.90   0.38   4.60   2.97   0.19   34.89   19.03   11.56  
   After IVS  72.26   32.30   0.13   16.70   7.40   0.22   99.19   69.05   9.91  
010          
   PBMC   2.30   8.45   0.50   1.60   1.10   0.02   8.73   26.51   5.32  
   After IVS   9.60   30.19   0.17   11.34   21.47   0.93   71.25   88.34   28.1  
011          
   PBMC   0.37   3.00   0.08   0.45   2.00   0.05   3.64   9.68   0.01  
   After IVS
 
3.91
 
57.44
 
0.41
 
1.73
 
17.17
 
0.21
 
61.58
 
97.71
 
22.37
 


% Tetramer binding

% IFN-γ

% CRA
UPN
IE1
pp65
Nonrelated
IE1
pp65
Nonrelated
IE1
pp65
Nonrelated
009          
   PBMC*  6.89   2.90   0.38   4.60   2.97   0.19   34.89   19.03   11.56  
   After IVS  72.26   32.30   0.13   16.70   7.40   0.22   99.19   69.05   9.91  
010          
   PBMC   2.30   8.45   0.50   1.60   1.10   0.02   8.73   26.51   5.32  
   After IVS   9.60   30.19   0.17   11.34   21.47   0.93   71.25   88.34   28.1  
011          
   PBMC   0.37   3.00   0.08   0.45   2.00   0.05   3.64   9.68   0.01  
   After IVS
 
3.91
 
57.44
 
0.41
 
1.73
 
17.17
 
0.21
 
61.58
 
97.71
 
22.37
 

Combined exposure of PBMCs to pp65/pp150-MVA and IE4-MVA was carried out as described in “Materials and methods.” Immunity to IE1316-324, pp65495-503, and nonrelated peptide p53149-157 was determined for HLA A*0201 donors 009, 010, and 011, as specified in “Materials and methods,” and listed as percentages. CRA killing is reported at E/T 100 for PBMCs and at E/T 20 for post-IVS cultures.

*

PBMC = fresh uncultured PBMC

After IVS = cultured cells after IVS

or Create an Account

Close Modal
Close Modal